Shandong Xinbo is a scientific research service enterprise integrating pharmacodynamic research, toxicological research, drug analysis and testing services, animal pathology testing, and medical device evaluation services. It is a high-tech enterprise and a provincial enterprise technology center in Shandong Province.

Shandong Xinbo has established Jinan Laboratory and Linyi Laboratory. Currently, it has built a pharmacology and toxicology research laboratory covering approximately 20,000 square meters, which meets NMPA/FDA GLP standards. The laboratory is equipped with over 800 domestic and international instruments and equipment. The toxicology research laboratory is capable of conducting single-dose toxicity tests, repeated-dose toxicity tests, safety pharmacology tests, reproductive toxicity tests, genetic toxicity tests, local toxicity tests, immunogenicity tests, and toxicokinetic tests in accordance with NMPA and FDA GLP standards.

The company is dedicated to providing professional contract research services for new drug and medical research institutions. Since its establishment in 2010, it has provided over 12,000 services to more than 630 pharmaceutical companies, new drug research institutions, and scientific research institutes both domestically and internationally. It has completed nearly 550 preclinical evaluation services for innovative drugs in accordance with domestic and international regulatory requirements, including small molecule drugs, biological macromolecule drugs, new preventive and therapeutic vaccines, and Chinese medicine/natural medicine evaluations. It has assisted research and development units in obtaining more than 100 clinical approvals for new drugs, and has also accumulated rich experience in the evaluation of therapeutic vaccines, cell and gene therapy drugs, which have developed rapidly in recent years. It has completed the evaluation of nearly 4,800 generic drug varieties.

In addition, the company continuously innovates and practices, breaks through barriers, and has made improvements and explorations in areas such as challenging administration techniques for young animals, continuous intravenous administration, and tracheal administration. These advancements have been maturely applied to safety evaluations. The company also pays attention to the needs of innovative development in the global pharmaceutical industry. Based on the key links of innovative drug research and development, and leveraging the experience accumulated from serving the pharmaceutical industry both domestically and internationally, it provides full-process preclinical research and development services for new drugs to the global pharmaceutical industry.